ABG Sundal Collier acted as exclusive financial advisor to IFE in connection with the sale of a majority stake in Agilera Pharma

On 9 April 2025, Institute for Energy Technology (“IFE”) announced the signing of an agreement to sell a majority stake in Agilera Pharma AS (“Agilera”) to PharmaLogic. Agilera is a spin-off from IFE and one of the only two independent companies in the world to produce commercial radiopharmaceutical therapies for cancer treatment. PharmaLogic is a leading contract development and manufacturing organization (CDMO) specialized in radiopharmaceuticals based in the US.
Through this acquisition, PharmaLogic partners with IFE to establish its European manufacturing footprint in Norway, tackle the growing market for radiopharmaceutical therapeutics and create a fully integrated, global CDMO specializing in radiopharmaceutical therapies. This transaction will build on Norway’s strong position within radiopharmaceuticals and further strengthen radiopharmacy as a Norwegian export industry.
ABG Sundal Collier acted as exclusive financial advisor to IFE in the transaction and would like to extend our gratitude for the vote of confidence.